Cargando…
MELD-Sarcopenia is Better than ALBI and MELD Score in Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation
BACKGROUND: The albumin bilirubin (ALBI) score and model of end stage liver disease (MELD) are prognostic in patients with hepatocellular carcinoma (HCC). Aim was to compare MELD-sarcopenia to MELD and ALBI scores in patients with HCC awaiting liver transplantation. METHODS: patients with HCC (n=262...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
West Asia Organization for Cancer Prevention
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607083/ https://www.ncbi.nlm.nih.gov/pubmed/34319020 http://dx.doi.org/10.31557/APJCP.2021.22.7.2005 |
_version_ | 1784602483380715520 |
---|---|
author | Alsebaey, Ayman Aliaa, Aliaa Rashed, Hanaa Said Elsabaawy, Maha Mohammad Ragab, Amr Aly, Rasha Abdelhafiz Badran, Hanaa |
author_facet | Alsebaey, Ayman Aliaa, Aliaa Rashed, Hanaa Said Elsabaawy, Maha Mohammad Ragab, Amr Aly, Rasha Abdelhafiz Badran, Hanaa |
author_sort | Alsebaey, Ayman |
collection | PubMed |
description | BACKGROUND: The albumin bilirubin (ALBI) score and model of end stage liver disease (MELD) are prognostic in patients with hepatocellular carcinoma (HCC). Aim was to compare MELD-sarcopenia to MELD and ALBI scores in patients with HCC awaiting liver transplantation. METHODS: patients with HCC (n=262) were included and followed up for 12 months. Baseline MELD, ALBI and MELD-sarcopenia models were calculated. RESULTS: The average age was 59.61 ±8.09 years. Most patients were males (69.5%), CTP class A (55.7%) and BCLC stage B (54.2%). Hepatitis C virus was the main cause of liver cirrhosis in most patients (88.9%). The average MELD, MELD-sarcopenia and median ALBI score were 10.65 ±2.54, 15.11 ±6.22 and -2.12 (0.74) respectively. Sarcopenia patients had higher MELD, ALBI and MELD-sarcopenia values. Patients with sarcopenia had lower survival (10.09 months) than those without (11.72 months). The ALBI, MELD and MELD-sarcopenia were associated with mortality. ALBI had AUROC of 0.717 (95% CI: 0.659 - 0.771), MELD had AUROC of 0.656 (95% CI: 0.595 - 0.713) and MELD-sarcopenia had AUROC of 0.798 (95% CI: 0.744 - 0.845). The ALBI and MELD scores had comparable AUROC (p=0.081). The MELD-sarcopenia had superior AUROC than MELD (p=0.001) and ALBI (p=0.05). CONCLUSION: MELD-sarcopenia is better prognostic model than the ALBI and MELD scores in HCC patients awaiting liver transplantation. |
format | Online Article Text |
id | pubmed-8607083 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | West Asia Organization for Cancer Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-86070832021-11-26 MELD-Sarcopenia is Better than ALBI and MELD Score in Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation Alsebaey, Ayman Aliaa, Aliaa Rashed, Hanaa Said Elsabaawy, Maha Mohammad Ragab, Amr Aly, Rasha Abdelhafiz Badran, Hanaa Asian Pac J Cancer Prev Research Article BACKGROUND: The albumin bilirubin (ALBI) score and model of end stage liver disease (MELD) are prognostic in patients with hepatocellular carcinoma (HCC). Aim was to compare MELD-sarcopenia to MELD and ALBI scores in patients with HCC awaiting liver transplantation. METHODS: patients with HCC (n=262) were included and followed up for 12 months. Baseline MELD, ALBI and MELD-sarcopenia models were calculated. RESULTS: The average age was 59.61 ±8.09 years. Most patients were males (69.5%), CTP class A (55.7%) and BCLC stage B (54.2%). Hepatitis C virus was the main cause of liver cirrhosis in most patients (88.9%). The average MELD, MELD-sarcopenia and median ALBI score were 10.65 ±2.54, 15.11 ±6.22 and -2.12 (0.74) respectively. Sarcopenia patients had higher MELD, ALBI and MELD-sarcopenia values. Patients with sarcopenia had lower survival (10.09 months) than those without (11.72 months). The ALBI, MELD and MELD-sarcopenia were associated with mortality. ALBI had AUROC of 0.717 (95% CI: 0.659 - 0.771), MELD had AUROC of 0.656 (95% CI: 0.595 - 0.713) and MELD-sarcopenia had AUROC of 0.798 (95% CI: 0.744 - 0.845). The ALBI and MELD scores had comparable AUROC (p=0.081). The MELD-sarcopenia had superior AUROC than MELD (p=0.001) and ALBI (p=0.05). CONCLUSION: MELD-sarcopenia is better prognostic model than the ALBI and MELD scores in HCC patients awaiting liver transplantation. West Asia Organization for Cancer Prevention 2021-07 /pmc/articles/PMC8607083/ /pubmed/34319020 http://dx.doi.org/10.31557/APJCP.2021.22.7.2005 Text en https://creativecommons.org/licenses/by/3.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License, (http://creativecommons.org/licenses/by/3.0/ (https://creativecommons.org/licenses/by/3.0/) ) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Article Alsebaey, Ayman Aliaa, Aliaa Rashed, Hanaa Said Elsabaawy, Maha Mohammad Ragab, Amr Aly, Rasha Abdelhafiz Badran, Hanaa MELD-Sarcopenia is Better than ALBI and MELD Score in Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation |
title | MELD-Sarcopenia is Better than ALBI and MELD Score in Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation |
title_full | MELD-Sarcopenia is Better than ALBI and MELD Score in Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation |
title_fullStr | MELD-Sarcopenia is Better than ALBI and MELD Score in Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation |
title_full_unstemmed | MELD-Sarcopenia is Better than ALBI and MELD Score in Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation |
title_short | MELD-Sarcopenia is Better than ALBI and MELD Score in Patients with Hepatocellular Carcinoma Awaiting Liver Transplantation |
title_sort | meld-sarcopenia is better than albi and meld score in patients with hepatocellular carcinoma awaiting liver transplantation |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607083/ https://www.ncbi.nlm.nih.gov/pubmed/34319020 http://dx.doi.org/10.31557/APJCP.2021.22.7.2005 |
work_keys_str_mv | AT alsebaeyayman meldsarcopeniaisbetterthanalbiandmeldscoreinpatientswithhepatocellularcarcinomaawaitinglivertransplantation AT aliaaaliaa meldsarcopeniaisbetterthanalbiandmeldscoreinpatientswithhepatocellularcarcinomaawaitinglivertransplantation AT rashedhanaasaid meldsarcopeniaisbetterthanalbiandmeldscoreinpatientswithhepatocellularcarcinomaawaitinglivertransplantation AT elsabaawymahamohammad meldsarcopeniaisbetterthanalbiandmeldscoreinpatientswithhepatocellularcarcinomaawaitinglivertransplantation AT ragabamr meldsarcopeniaisbetterthanalbiandmeldscoreinpatientswithhepatocellularcarcinomaawaitinglivertransplantation AT alyrashaabdelhafiz meldsarcopeniaisbetterthanalbiandmeldscoreinpatientswithhepatocellularcarcinomaawaitinglivertransplantation AT badranhanaa meldsarcopeniaisbetterthanalbiandmeldscoreinpatientswithhepatocellularcarcinomaawaitinglivertransplantation |